<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a case of an 18-year-old female, who was diagnosed as having systemic <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> with chief complaints of <z:e sem="disease" ids="C0456909" disease_type="Disease or Syndrome" abbrv="">vision loss</z:e> in the right eye and redness and pain in both eyes </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to an anterior necrotizing <z:hpo ids='HP_0100532'>scleritis</z:hpo>, she had several attacks of <z:hpo ids='HP_0100654'>retrobulbar neuritis</z:hpo> and lateral rectus <z:hpo ids='HP_0100614'>myositis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>She responded well to i.v. and topical <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and her subsequent attacks were treated with i.v. <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (500 mg on presentation and on Days 7, 10, 12, 15, and 20; the cycle was repeated every 20 days) </plain></SENT>
<SENT sid="3" pm="."><plain>She benefited on this treatment and her vision improved dramatically </plain></SENT>
<SENT sid="4" pm="."><plain>Her final acuity of 20/50 was thought to be due to presumed previous attacks of <z:hpo ids='HP_0100653'>optic neuritis</z:hpo> and anterior segment <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>During the five-month follow-up period, she had no other attacks </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> and <z:mp ids='MP_0001845'>inflammation</z:mp> are common in <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> and sometimes <z:mp ids='MP_0005048'>thrombosis</z:mp> and vasculitic changes may cause a decrease in vision </plain></SENT>
<SENT sid="7" pm="."><plain>In this case, the immunosuppressive therapy helped attenuate the inflammatory vasculitic episodes during the disease course </plain></SENT>
</text></document>